title: In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine.
abstract: Actively targeted theranostic nanomedicine may be the key for future personalized cancer management. Although numerous types of theranostic nanoparticles have been developed in the past decade for cancer treatment, challenges still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities. Here, we report the design, synthesis, surface engineering, and in vivo active vasculature targeting of a new category of theranostic nanoparticle for future cancer management. Water-soluble photothermally sensitive copper sulfide nanoparticles were encapsulated in biocompatible mesoporous silica shells, followed by multistep surface engineering to form the final theranostic nanoparticles. Systematic in vitro targeting, an in vivo long-term toxicity study, photothermal ablation evaluation, in vivo vasculature targeted imaging, biodistribution and histology studies were performed to fully explore the potential of as-developed new theranostic nanoparticles.
authors.affiliation: †Department of Radiology, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.affiliation: †Department of Radiology, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Hao
authors.initials: H
authors.lastname: Hong
authors.affiliation: ‡Materials Science Program, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Shreya
authors.initials: S
authors.lastname: Goel
authors.affiliation: §Department of Medical Physics, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Graves
authors.affiliation: †Department of Radiology, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Hakan
authors.initials: H
authors.lastname: Orbay
authors.affiliation: §Department of Medical Physics, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Emily B
authors.initials: EB
authors.lastname: Ehlerding
authors.affiliation: ‡Materials Science Program, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Sixiang
authors.initials: S
authors.lastname: Shi
authors.affiliation: ⊥TRACON Pharmaceuticals, Inc., San Diego, California 92122, United States.
authors.forename: Charles P
authors.initials: CP
authors.lastname: Theuer
authors.affiliation: §Department of Medical Physics, University of Wisconsin - Madison, Wisconsin 53705, United States.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Nickles
authors.affiliation: †Department of Radiology, University of Wisconsin - Madison, Wisconsin 53705, United States.|‡Materials Science Program, University of Wisconsin - Madison, Wisconsin 53705, United States.|§Department of Medical Physics, University of Wisconsin - Madison, Wisconsin 53705, United States.|∥University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705, United States.
authors.forename: Weibo
authors.initials: W
authors.lastname: Cai
mesh_terms: D055011:Ablation Techniques; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003300:Copper / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004337:Drug Carriers / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000071063:Endoglin; D005260:Female; D006571:Heterocyclic Compounds / Q000737:chemistry; D006573:Heterocyclic Compounds, 1-Ring; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D049329:Nanostructures / Q000737:chemistry*; D009389:Neovascularization, Pathologic / Q000628:therapy*; D011092:Polyethylene Glycols / Q000737:chemistry; D016062:Porosity; D049268:Positron-Emission Tomography; D012822:Silicon Dioxide / Q000737:chemistry*; D000068936:Theranostic Nanomedicine / Q000379:methods*; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D000071063:Endoglin; C502004:Eng protein, mouse; D006571:Heterocyclic Compounds; D006573:Heterocyclic Compounds, 1-Ring; D047908:Intracellular Signaling Peptides and Proteins; D011092:Polyethylene Glycols; C048993:1,4,7-triazacyclononane-N,N',N''-triacetic acid; D012822:Silicon Dioxide; D003300:Copper; C017846:cupric sulfide
keywords: CuS; mesoporous silica nanoparticle; photothermal ablation; theranostic nanomedicine; vasculature targeting
references.citation: Nano Lett. 2014 Feb 12;14(2):923-32
references.pmid: 24467566
references.citation: Angiogenesis. 2013 Jul;16(3):663-74
references.pmid: 23471463
references.citation: Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79
references.pmid: 20691229
references.citation: Int J Mol Sci. 2015;16(1):660-76
references.pmid: 25561223
references.citation: Adv Mater. 2011 Aug 16;23(31):3542-7
references.pmid: 21735487
references.citation: ACS Nano. 2011 Dec 27;5(12):9761-71
references.pmid: 22059851
references.citation: J Am Chem Soc. 2012 Apr 4;134(13):5722-5
references.pmid: 22420312
references.citation: Mol Pharm. 2012 Aug 6;9(8):2339-49
references.pmid: 22784250
references.citation: ACS Nano. 2012 Mar 27;6(3):2361-70
references.pmid: 22339280
references.citation: Small. 2014 May 28;10(10):1887-93
references.pmid: 24591109
references.citation: J Am Chem Soc. 2010 Nov 3;132(43):15351-8
references.pmid: 20942456
references.citation: J Clin Invest. 2011 Jul;121(7):2768-80
references.pmid: 21670497
references.citation: Cancer Res. 2006 Oct 1;66(19):9673-81
references.pmid: 17018625
references.citation: Theranostics. 2014;4(6):660-77
references.pmid: 24723986
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2585-92
references.pmid: 22689807
references.citation: Life Sci. 2012 Mar 10;90(11-12):381-7
references.pmid: 22326503
references.citation: J Nucl Med. 2014 Dec;55(12):1919-22
references.pmid: 25413134
references.citation: J Nucl Med. 2006 Jul;47(7):1172-80
references.pmid: 16818952
references.citation: ACS Nano. 2011 May 24;5(5):3744-57
references.pmid: 21513307
references.citation: Mol Pharm. 2013 Jul 1;10(7):2749-56
references.pmid: 23738915
references.citation: Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):1-9
references.pmid: 24380040
references.citation: Cardiovasc Res. 2010 Apr 1;86(1):12-9
references.pmid: 19812043
references.citation: Sci Rep. 2014;4:5080
references.pmid: 24875656
references.citation: Acc Chem Res. 2011 Oct 18;44(10):1029-38
references.pmid: 21545096
references.citation: Drug Discov Today. 2012 Sep;17(17-18):928-34
references.pmid: 22484464
references.citation: Curr Cancer Drug Targets. 2003 Dec;3(6):427-32
references.pmid: 14683500
references.citation: ACS Nano. 2013 Oct 22;7(10):9027-39
references.pmid: 24083623
references.citation: Curr Drug Deliv. 2011 Jan;8(1):135-43
references.pmid: 21034418
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4820-9
references.pmid: 22767667
references.citation: Nano Today. 2009 Oct 1;4(5):399-413
references.pmid: 20161038
references.citation: Acc Chem Res. 2011 Oct 18;44(10):1050-60
references.pmid: 21919457
references.citation: Biomaterials. 2013 Nov;34(33):8323-32
references.pmid: 23932288